Generic Cleocin Launched by Mylan

Article

Mylan has launched clindamycin palmitate hydrochloride for oral solution USP, 75 mg/5mL, which is the generic version of Pharmacia and Upjohn's Cleocin solution.

Mylan has launched clindamycin palmitate hydrochloride for oral solution USP, 75 mg/5mL, which is the generic version of Pharmacia and Upjohn’s Cleocin solution.

The FDA granted final approval for Mylan’s abbreviated new drug application for the solution, which can treat serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci, and staphylococci when less toxic alternatives are inappropriate.

Clindamycin palmitate hydrochloride had US sales of nearly $31 million for the fiscal year ending on March 31, 2016, according to IMS Health.

Clostridium difficile-associated diarrhea (CDAD) has been reported in patients who use antibacterial agents, including Cleocin. CDAD can range in severity from mild diarrhea to fatal colitis.

The most common adverse effects associated with Cleocin are abdominal pain, skin rashes, nausea, and vomiting.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.